## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 99,371)

In application of:

Thomason et al.

Serial No. 09/391,861

Filed: September 7, 1999

For: Fibroblast Growth Factor-like

**Polypeptides** 

**Before the Examiner:** C. Stroup

**Group Art Unit:1633** 

## RESPONSE TO THE RESTRICTION REQUIREMENT MAILED JANUARY 27, 2000 AND PRELIMINARY AMENDMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Responsive to the Restriction Requirement, mailed January 27, 2000, Applicants elect withy traverse to prosecute claims 1-5, 7-13 and 36, designated as Group I by the Examiner.

The basis for Applicants' traversal of the restriction requirement is that certain of the claims are sufficiently related as to pose no excess burden on the Patent Office to examine these claims together. For example, elected claims 1-5, 7-13 and 36 are in the same class as claims 17-19, 21 and 32, designated as group III by the Examiner.

## **AMENDMENT**

## IN THE CLAIMS:

Please amend the following claims:

1. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

McDONNELL BOEHNEN HULBERT & BERGHOFF 300 South Wacker Drive Chicago, Illinois 60606 (312) 913-0001